For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Arrowhead Research Corporation

USPTO Granted Patents = 18

EPO Patents = 7

Trademarks = 2

Forward Citations = 23

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Jon E Chatterton (9 out of 47 patents)

Abbot F Clark (3 out of 58 patents)

Gregory Hinkle (2 out of 96 patents)

4. Stuart Milstein (2 out of 91 patents)

5. Michael Houghton (2 out of 109 patents)

6. Emma Hickman (2 out of 20 patents)

7. John M Yanni (2 out of 53 patents)

8. Daniel A Gamache (2 out of 38 patents)

9. Steven T Miller (2 out of 28 patents)

10. Martin B Wax (2 out of 15 patents)

11. Jang Hyun Han (2 out of 19 patents)

12. Satyanarayana Kuchimanchi (1 out of 38 patents)

13. Markus Hossbach (1 out of 20 patents)

14. Gino Van Heeke (1 out of 20 patents)

15. Henry Luke Danahay (1 out of 13 patents)

18 patents: Sort by Forward Citations

1. 9371529 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions (2016-06-21),

2. 9347062 - Interfering RNA delivery system and uses thereof (2016-05-24),

3. 9289514 - Low density lipoprotein receptor-mediated siRNA delivery (2016-03-22),

4. 9233170 - Interfering RNA delivery system and uses thereof (2016-01-12),

5. 9206428 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2015-12-08),

6. 9173896 - RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions (2015-11-03),

7. 9150862 - siRNA targeting VEGFA and methods for treatment in vivo (2015-10-06),

8. 9139834 - RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis (2015-09-22),

9. 9139833 - Modified small interfering RNA molecules and methods of use (2015-09-22),

10. 9133462 - dsRNA for treating viral infection (2015-09-15),

11. 9114152 - Transferrin/transferrin receptor-mediated siRNA delivery (2015-08-25),

12. 9096637 - Organic compositions to treat HSF1-related diseases (2015-08-04),

13. 9084808 - Modified small interfering RNA molecules and methods of use (2015-07-21),

14. 9080175 - Organic compositions to treat Beta-ENaC-related diseases (2015-07-14),

15. 9074212 - RNAi inhibition of alpha-ENaC expression (2015-07-07),

Arrowhead Research Corporation is a biopharmaceutical company focused on the development and commercialization of novel therapeutics primarily for the treatment of diseases in oncology, as well as other areas of high unmet medical need. The company utilizes its proprietary Targeted RNAi Molecule (TRiM™) platform to develop RNAi-based therapeutics that selectively and efficiently silence disease-causing genes. Arrowhead Research Corporation aims to improve patients' lives through innovative research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#35 in Pasadena, CA

#4,156 in California

#17,417 in US

#33,187 in the World

Pasadena, CA, United States of America

Arrowhead Research Corporation

Forward Citations = 23

49 inventors:

Jon E Chatterton (9 out of 47 patents)

Abbot F Clark (3 out of 58 patents)

Gregory Hinkle (2 out of 96 patents)

4. Stuart Milstein (2 out of 91 patents)

5. Michael Houghton (2 out of 109 patents)

Please report any incorrect information to support@idiyas.com

Loading…